Skip to content
- Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors.
- Golder A, Nelson L, Tighe A, Barnes B, Coulson-Gilmer C, Morgan RD, McGrail JC, Taylor SS.
- NAR Cancer. 2022 Nov 12 [eCollection 2022 Dec];4(4):zcac036. doi: 10.1093/narcan/zcac036.
- Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers.
- Ogony J, Hoskin TL, Stallings-Mann M, Winham S, Brahmbhatt R, Arshad MA, Kannan N, Peña A, Allers T, Brown A, Sherman ME, Visscher DW, Knutson KL, Radisky DC, Degnim AC.
- Breast Cancer Res Treat. 2022 Nov 16. doi: 10.1007/s10549-022-06786-y. Epub ahead of print.
- BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy.
- Soni A, Lin X, Mladenov E, Mladenova V, Stuschke M, Iliakis G.
- Cancers (Basel). 2022 Nov 16;14(22):5619. doi: 10.3390/cancers14225619.
- Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.
- Franzese O, Graziani G.
- Cancers (Basel). 2022 Nov 16;14(22):5633. doi: 10.3390/cancers14225633.
- Characterization of Oncology Clinical Trials Using Germline Genetic Data.
- Kammula AV, Schäffer AA, Rajagopal PS.
- JAMA Netw Open. 2022 Nov 1;5(11):e2242370. doi: 10.1001/jamanetworkopen.2022.42370.